Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.

Sun Z, Zhang C, Wang T, Shi P, Tian X, Guo Y.

J Cancer Res Ther. 2019;15(4):933-940. doi: 10.4103/jcrt.JCRT_208_19.

2.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.

PMID:
23117856
3.

Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.

Dong H, Hu J, Zou K, Ye M, Chen Y, Wu C, Chen X, Han M.

Mol Cancer. 2019 Jan 8;18(1):3. doi: 10.1186/s12943-018-0931-9.

5.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

PMID:
16887935
6.

Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer.

Si H, Chen P, Li H, Wang X.

Am J Transl Res. 2019 May 15;11(5):3213-3225. eCollection 2019.

7.

SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.

Dong H, Wang W, Mo S, Chen R, Zou K, Han J, Zhang F, Hu J.

J Exp Clin Cancer Res. 2018 Aug 29;37(1):202. doi: 10.1186/s13046-018-0875-3.

8.

Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation.

Dong H, Wang W, Mo S, Liu Q, Chen X, Chen R, Zhang Y, Zou K, Ye M, He X, Zhang F, Han J, Hu J.

J Cell Mol Med. 2018 Oct;22(10):4935-4947. doi: 10.1111/jcmm.13758. Epub 2018 Jul 31.

9.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
10.

Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.

Dong H, Wang W, Chen R, Zhang Y, Zou K, Ye M, He X, Zhang F, Han J.

Int J Oncol. 2018 Sep;53(3):1013-1026. doi: 10.3892/ijo.2018.4467. Epub 2018 Jul 3.

11.

LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.

Zhu QN, Wang G, Guo Y, Peng Y, Zhang R, Deng JL, Li ZX, Zhu YS.

Oncotarget. 2017 Sep 21;8(54):91990-92003. doi: 10.18632/oncotarget.21121. eCollection 2017 Nov 3.

12.

H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells.

Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li TL, Cai JQ, Zhou HH, Zhu YS.

Oncol Rep. 2015 Jun;33(6):3045-52. doi: 10.3892/or.2015.3899. Epub 2015 Apr 3.

PMID:
25846769
13.

tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.

Sun C, Yang F, Zhang Y, Chu J, Wang J, Wang Y, Zhang Y, Li J, Li Y, Fan R, Li W, Huang X, Wu H, Fu Z, Jiang Z, Yin Y.

Cell Physiol Biochem. 2018;49(2):419-431. doi: 10.1159/000492977. Epub 2018 Aug 28.

14.

Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process.

Gao H, Hao G, Sun Y, Li L, Wang Y.

Onco Targets Ther. 2018 Nov 9;11:8001-8012. doi: 10.2147/OTT.S172379. eCollection 2018.

15.

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.

16.

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.

Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.

BMC Cancer. 2014 Nov 24;14:869. doi: 10.1186/1471-2407-14-869.

17.

Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X.

Clin Breast Cancer. 2015 Dec;15(6):448-457.e2. doi: 10.1016/j.clbc.2015.06.001. Epub 2015 Jun 19.

18.

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.

Baldassarre T, Truesdell P, Craig AW.

Breast Cancer Res. 2017 Oct 3;19(1):110. doi: 10.1186/s13058-017-0900-z.

19.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.

O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.

Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17.

20.

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.

Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E.

J Biol Chem. 2011 May 27;286(21):19127-37. doi: 10.1074/jbc.M110.216887. Epub 2011 Apr 6.

Supplemental Content

Support Center